Don’t miss this live webinar to hear our President and CEO, Alessandro Maselli, discuss the evolving role CDMOs play in the biopharmaceutical market, and what’s next for Catalent as it progresses its shift from public to private ownership under its previously announced transaction with Novo Holdings. Register today! https://ow.ly/UNvX50StQQ0
Catalent Pharma Solutions’ Post
More Relevant Posts
-
Ligand’s Captisol technology platform has helped optimize the solubility and stability of drugs for some of the world’s leading biopharmaceutical companies including Merck Pfizer Amgen and Gilead Sciences. Today there are more than 15 Captisol-enabled™ products approved worldwide. The leaders of our Captisol team, Drs. Vince Antle and James Pipkin, recently sat down with Lawrence Business Magazine to discuss how this unique technology has changed how drugs are developed and formulated. Read the article here: https://bit.ly/4bRjJtv
To view or add a comment, sign in
-
-
Read our article in the European Biopharmaceutical Review (EBR) to learn more about how Just - Evotec Biologics is bringing #continuousbiomanufacturing to Europe.
Continuous biomanufacturing arrives in Europe! We’re thrilled to announce that Just - Evotec Biologics, a pioneer in #ContinuousBiomanufacturing, is on track to launch its state-of-the-art J.POD® Toulouse facility this September! This expansion marks a significant milestone in biomanufacturing innovation, bringing cutting-edge technology and increased production capabilities to the European biopharmaceutical landscape. Stay tuned for more updates and read about our groundbreaking facility in the latest issue of the European Biopharmaceutical Review: https://hubs.ly/Q02CpN_T0 #Biomanufacturing #Innovation #Biopharma #JustEvotecBiologics
To view or add a comment, sign in
-
-
Engineered Scientific Data is the Force Multiplier for AI
Join us along with our partner Semantic Web Company (SWC) for our joint webinar in December while we address several crucial aspects of maximizing the value of scientific data in the biopharmaceutical industry. Register Today! https://lnkd.in/gfz2BeiU
To view or add a comment, sign in
-
-
In case you missed it! Following the addition of StemSight - Vision Unlimited to our family of licensees earlier this year, our CEO, John E. Milad, and StemSight’s CCO, Ross Macdonald, discuss how #CRISPRCas9 has become a transformative tool in life sciences. If you haven’t already, read our latest article in European Biopharmaceutical Review (EBR): https://shorturl.at/0dgFD
To view or add a comment, sign in
-
-
Another successful project in the books ✅ This time we're sharing the outcome of our work with Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company in need of a refresh for its #NewHavenCT office. Check out how it all turned out! 👇 #buildwithcatalyst
To view or add a comment, sign in
-
Full scope... full solution... fully appreciating and anticipating the expectations and needs of our customers. That's what KBI Biopharma is all about. Today marks a pivotal point in our corporate journey. We can now carry through the productivity and quality of our projects to the end point - in a streamlined fashion. #cdmo #endtoendsolutions #onestopshop #contractmanufacturing #processdevelopment #fillfinish #downstreamprocessing
KBI Biopharma and Argonaut Manufacturing Services Inc. announced today a strategic alliance to support global biopharmaceutical companies with integrated drug substance and drug product solutions. “At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics. [Argonaut’s] commitment to quality and efficiency aligns perfectly with our own values and vision. This collaboration represents a new era of collaboration and innovation in the biopharma industry,” said J.D. Mowery, President and CEO of KBI Biopharma. Read the full release: https://hubs.la/Q02gvd0N0 #KBIBiopharma #CDMO #Biopharma
To view or add a comment, sign in
-
-
STARTING SOON: Learn about Soligenix (NASDAQ: SNGX) in today's webinar. $SNGX is a biopharmaceutical company that focuses on orphan diseases with multiple late-stage clinical assets, one with a successful Phase 3 data readout. REGISTER HERE: https://ow.ly/BVoS50S0VC4
To view or add a comment, sign in
-
-
Clinical Trial Supplies Market to grow by USD 1.19 billion from 2022 to 2027 | The growth of the biopharmaceutical industry drives the market growth - Technavio: NEW YORK, Nov. 12, 2023 /PRNewswire/ -- The clinical trial supplies market size is expected to grow by USD 1.19 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of over 8.48% during the forecast period, according to Technavio Research. The growth...
To view or add a comment, sign in
-
🌟 Join this upcoming webinar with Claritas Rx for a fireside chat featuring Mike McDole from Aveo, an oncology-focused biopharmaceutical company. In this discussion, the featured speakers will explore the challenges and opportunities within trade operations and customer base expansion. 💡 Learn more and register here: https://buff.ly/40pd4my #PatientData #PatientSupport #PatientManagement
To view or add a comment, sign in
-
-
Today, our President and CEO, Lars Petersen, will be a distinguished speaker on a panel at the Biomanufacturing World Summit in San Diego at 1:55PM! 🌐 Panel Topic will cover "CDMOs as Critical Partners in the Biopharmaceutical Ecosystem: Challenges and Trends in the Past, Present, and Future." Lars Petersen will delve into the transformation of Contract Development and Manufacturing Organizations (CDMOs) from service providers to indispensable partners in the biopharmaceutical ecosystem. Join us as he analyzes the challenges faced in meeting the rising demand for biopharmaceutical products and explores strategies to overcome capacity limitations. Don't miss this insightful discussion! Gain valuable insights into the evolving landscape of the biopharmaceutical industry. #Biomanufacturing #CDMO #BWS2023 #BiopharmaInnovation #DrugDevelopment
To view or add a comment, sign in
-